Recorded June 19, 2017 | On-Demand Webinar
With the ever-increasing number of states legalizing cannabis for medical and recreational use, many have been asking how FDA’s regulatory paradigm might apply to this burgeoning industry. During this webinar, speakers will provide an overview of the current state of regulation and explore how it intersects with FDA-regulated products. The implications for clinical research being conducted for INDs and NDAs, as well as issues related to edibles and dietary supplements, such as good manufacturing practices, will be discussed.
Jonathan A. Havens, Associate, Saul Ewing LLP
Colin Mudd, National Compliance Director, MC Management LLC
Douglas Throckmorton, Deputy Center Director for Regulatory Programs, CDER, FDA
Moderated by Emily Leongini, Associate, Arent Fox LLP